Announcements Trials

Browse Landscape

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Non-Small-Cell Lung 39 Squamous Cell Carcinoma of Head and Neck 20 Lung Neoplasms 20 Oropharyngeal Neoplasms 9 Parkinson Disease 4, Autosomal Dominant Lewy Body 8 Urinary Bladder Neoplasms 7 Uterine Cervical Neoplasms 6 Endometrial Neoplasms 6 Carcinoma 6 Pancreatic Neoplasms 5 Mouth Neoplasms 5 Colorectal Neoplasms 5 Cholangiocarcinoma 5 Biliary Tract Neoplasms 5 Neoplasms 4 Neoplasm Metastasis 4 Nasopharyngeal Carcinoma 4 Laryngeal Neoplasms 4 Head and Neck Neoplasms 4 Carcinoma, Squamous Cell 4 Mesothelioma, Malignant 3 Lymphoid Interstitial Pneumonia 3 Hypopharyngeal Neoplasms 3 Esophageal Squamous Cell Carcinoma 3 Triple Negative Breast Neoplasms 2 Tongue Neoplasms 2 Stomach Neoplasms 2 Small Cell Lung Carcinoma 2 Salivary Gland Neoplasms 2 Rectal Neoplasms 2

Interventions

pembrolizumab 1 erdafitinib 1 enfortumab vedotin 1 Midazolam 1 Metformin 1 Gemcitabine 1 Cisplatin 1 Carboplatin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Urothelial Cancer × Cisplatin × 30 days × Clear all

NCT04223856 2026-05-29

EV-302

Astellas Pharma Inc

Phase 3 Active not recruiting

886 enrolled 12 charts 1 FDA

Urothelial Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡